This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBDC Apotheca Biosciences (CBDC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Apotheca Biosciences Stock (NASDAQ:CBDC) 30 days 90 days 365 days Advanced Chart Get Apotheca Biosciences alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$0.00▼$0.0852-Week Range$0.00▼$0.31VolumeN/AAverage Volume21,204 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulations, and delivery technologies for the healthcare and consumer care industry in the United States. The company's products include transdermal, sublingual, and nasal delivery devices for dosing of cannabinoids. It also provides CBD pain cream, gel capsules, patches, and sleep tablets; and Promed, anti-aging and cosmetic products. The company was incorporated in 2014 and is based in Saint Petersburg, Florida. Read More Receive CBDC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apotheca Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBDC Stock News HeadlinesApotheca Biosciences IncFebruary 18, 2025 | thestreet.comThe Digital Dollar Project Publishes a Risk Framework for Consideration of a U.S. CBDCJuly 4, 2023 | finance.yahoo.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 13 at 2:00 AM | Banyan Hill Publishing (Ad)The Digital Currency Monetary Authority (DCMA) Launches an International Central Bank Digital Currency (CBDC)April 16, 2023 | finance.yahoo.comFlorida Governor Ron DeSantis proposes banning a digital currency from the Fed, arguing it will stifle innovation and promote surveillanceMarch 24, 2023 | markets.businessinsider.comWe're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash WiselyFebruary 27, 2023 | finance.yahoo.comJapan Joins the CBDC Race, Will Conduct Tests in AprilFebruary 19, 2023 | 247wallst.comHM Treasury Seeking Head of CBDC as UK Moves Closer to the Digital PoundJanuary 27, 2023 | 247wallst.comSee More Headlines CBDC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Apotheca Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apotheca Biosciences investors own include SoFi Technologies (SOFI), Andersons (ANDE), British American Tobacco (BTI), Copa (CPA), Cronos Group (CRON), FREYR Battery (FREY) and Kraft Heinz (KHC). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CBDC CIK1632053 Webwww.apothecabiosciences.com Phone727-228-3994FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CBDC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apotheca Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apotheca Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
